Shares of Viela Bio VIE were flat in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share were up 36.17% year over year to ($0.60), which beat the estimate of ($0.70).
Revenue of $9,336,000 declined by 68.88% from the same period last year, which beat the estimate of $5,550,000.
Outlook
Viela Bio hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Technicals
52-week high: $70.66
Company's 52-week low was at $25.02
Price action over last quarter: Up 50.07%
Company Overview
Viela Bio Inc is a clinical-stage biotechnology company engaged in developing and commercializing transformative treatments for severe inflammation and autoimmune diseases. Its product inebilizumab, is a humanized monoclonal antibody, designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.